Certara to Participate in Upcoming Investor Conferences
Certara (Nasdaq: CERT), a leader in model-informed drug development, has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Certara (Nasdaq: CERT), a leader in model-informed drug development, has announced its participation in two upcoming investor conferences. The company will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 4:05 p.m. ET and the Baird Global Healthcare Conference on September 11 at 10:15 a.m. ET.
Both conference presentations will be available via live webcasts on Certara's investor relations website at https://ir.certara.com. These webcasts will remain accessible for replay for at least 90 days after the events. This participation provides investors with opportunities to gain insights into Certara's operations and future prospects directly from the company's management.
Details
News Market Reaction – CERT
The recorded move for CERT in the trading session of this news was +0.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference
Date and Time: Wednesday, September 4 at 4:05 p.m. ET
- Baird Global Healthcare Conference
Date and Time: Wednesday, September 11 at 10:15 a.m. ET
Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.